---
title: "GSK executives acquire shares under company reward plan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286434027.md"
description: "GSK executives, including the President of Europe and CFO, acquired shares under the company's Share Reward Plan on May 12, 2026, at £18.6559 per share. These transactions, while small, enhance transparency regarding insider dealings and align management with shareholders. The latest analyst rating for GSK stock is a Hold with a £21.00 price target. Spark's AI Analyst rates GSK as Neutral, citing strong financial performance but offset by weak technical momentum and financial risks. GSK is a global biopharmaceutical company focused on medicines and vaccines."
datetime: "2026-05-14T14:33:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286434027.md)
  - [en](https://longbridge.com/en/news/286434027.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286434027.md)
---

# GSK executives acquire shares under company reward plan

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

An update from GlaxoSmithKline ( (GB:GSK) ) is now available.

GSK has disclosed a series of routine share dealings by senior executives under its Share Reward Plan, with ordinary shares acquired on 12 May 2026 on the London Stock Exchange. Participants include the President of Europe, the Chief Financial Officer, senior legal and corporate development leaders, and heads of global supply chain, global affairs and global health businesses, underscoring ongoing equity-based alignment between management and shareholders.

The transactions involve small volumes of partnership and matching shares at a price of £18.6559 per share, indicating incremental increases in executive equity holdings rather than major market moves. While financially immaterial at the group level, such notifications enhance transparency of insider dealings and provide investors with visibility into management’s participation in long‑term share incentive arrangements.

The most recent analyst rating on (GB:GSK) stock is a Hold with a £21.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

**Spark’s Take on GSK Stock**

According to Spark, TipRanks’ AI Analyst, GSK is a Neutral.

The score is driven primarily by solid underlying financial performance (strong margins and improved earnings) and supportive valuation (low P/E with a ~3.47% yield). These positives are partially offset by weak technical momentum (below key moving averages with negative MACD) and financial risk factors including meaningful leverage and uneven free-cash-flow consistency.

To see Spark’s full report on GSK stock, click here.

**More about GlaxoSmithKline**

GSK plc is a global biopharmaceutical company focused on developing, manufacturing and commercialising medicines and vaccines. The group targets major therapeutic areas and public health needs worldwide, leveraging a broad research pipeline and established commercial footprint across key pharmaceutical markets.

**Average Trading Volume:** 9,014,671

**Technical Sentiment Signal:** Buy

**Current Market Cap:** £75.51B

See more data about GSK stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [GSK.US](https://longbridge.com/en/quote/GSK.US.md)
- [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md)

## Related News & Research

- [GSK: Japan's MHLW Expands Eligible Population For Arexvy](https://longbridge.com/en/news/286723820.md)
- [<![CDATA[Pharmaceutical Executive Daily: GSK Enters Collaboration to Support Launch of Bepirovirsen]]>](https://longbridge.com/en/news/285984513.md)
- [GSK (LON:GSK) Insider Purchases £130.62 in Stock](https://longbridge.com/en/news/286511281.md)
- [GSK China Hepatitis B Push Raises Questions For Valuation And Dividend Risks](https://longbridge.com/en/news/285980824.md)
- [<![CDATA[GSK Enters Exclusive Collaboration with SBP Group to Accelerate Bepirovirsen at Launch in Mainland China ]]>](https://longbridge.com/en/news/285955820.md)